Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LL thus far is a failed compound, and worth $200 million under the best conditions.
With Leronlimab stuck inside a toxic financed negative equity stock promotion scheme and it's worthless.
Free Leronlimab!!! The self touted miracle drug from $CYDY!!
""Death By Nader""
Leronlimab is only worth $200 million TOPS, and $CYDY as a corporate entity is at NEGATIVE EQUITY thus making the common stock worthless by most financial measures.
also on value, the inventory is worthless too, that will be the next SEC item to be challenged on $CYDY's accounting.
Bicker all one wants on the investigations and who's to blame, but regardless $CYDY common equity is garbage.
Added small quantities today at $17 (original stink bid) and $16.50, and I have some Jan $20 call's that were based on Dr. M timeline... Doh...that play is way riskier than I expected as I normally never play current month option contracts.
So all tanned up and relaxed from Mexico?
Ready for the next stage of S1R science?
I am. ;)
Many firms are starting to charge commission for OTC trades.
I expect retail volume to start shifting away from OTC to where the new action is on the online brokerage apps and options.
This is BAD news for PIPE runners who want to sell their cheap 6 month held discounted stock.
We all agree that the stock price was artificially manipulated to $10.01.
"Da SEC will be in touch. Dats not a guess"
Oh we agree, it's all in the 10-K and judicial discovery. It's not "will be", they ARE in touch.
Down 89.91% is due to "manipulation" but the pump to $10.01 was on $CYDY merits?
The financial fact of the matter is the common equity is worthless once the capital structure is reviewed with the vendors, toxic debt, preferred shares...etc. are accounted for.
PIPE runners and MM's will do their best to keep the churn above $1 as long as possible to accommodate the long shares held 6 months and scheduled to be sold by the warrant holders and other entities compensated with discounted stock.
So factually the height of the pump ($10.01) to today is a loss of 89.81%
Lets have the facts this year.
In the meantime, $CYDY stock continues below $1...
Connect the dots...
The $CYDY saga reads like an OTCBB pump of a bygone era, just accelerated via social media.
$CYDY as a corporate entity is coming to and end, and the common equity will be worthless.
The compound LL and CCR5 as a treatment has yet to be proven or disproven, and won't be for many more years to come.
The fact of the matter is LL is dead in the water as long as $CYDY owns it.
$CYDY was and is an alleged "pump and dump" that has accomplished very little except sell stock.
CYDY: Just checking in here, why the PPS drop? This was multi dollars not long ago. I traded this back in 2015 before the big run.
Even I caught the listing of "Inventory" as a current asset questionable accounting. Especially when in reality any sort of approval was nowhere close.
131. On February 18, 2021, the SEC sent CytoDyn’s CFO, Defendant Mulholland, a letter regarding the Company’s Form 10-K for the Fiscal Year ended May 31, 2020. In the letter, which was posted to the EDGAR website, the SEC issued targeted inquiries concerning CytoDyn’s BLA, specifically: (i) the timeline of CytoDyn’s communications with the FDA prior to submitting the BLA; (ii) how the RTF impacted CytoDyn’s timing in respect to efforts to capitalize inventory with respect to leronlimab; (iii) the nature of additional information required by the FDA in order to resubmit the BLA; and (iv) “why your projected date for resubmitting the BLA keeps slipping.”
132. After reviewing CytoDyn’s March 23, 2021 response, on April 16, 2021, the SEC issued another letter to Mulholland. In the letter, which was posted to the EDGAR website, the SEC asserted that certain responses of CytoDyn failed to sufficiently respond to the SEC’s inquiries, including responses “to support management’s assertion that prelaunch inventory represented an asset at each date it was capitalized” and questioned the appropriateness of CytoDyn’s capitalization conclusions. Specifically: ? ? ? You assert that your meetings with the FDA addressed safety and efficacy of the drug. However, the FDA’s July 2020 Refusal to File letter states that your Biologics License Application omitted information necessary for the FDA to perform a substantive review of the product’s safety and effectiveness. You indicate that “…current scientific work being performed by the Company to complete a successful resubmission of the Company’s BLA” is ongoing and that you do not expect to resubmit your BLA until midcalendar year 2021 or shortly thereafter. You assert that you manufactured leronlimab consistent with cGMP standards. However, we note that the FDA’s September 20, 2020, response to your list of questions related to the Refusal to File letter continued to reference issues with your clinical and statistical data, device related issues, and chemical manufacturing and control related issues.
I thought it was hillarious that discovery from the CYDY versus Amarex lawsuit provided the "smoking gun" for this class action lawsuit against $CYDY.
This is an absolute MUST read for what has actually been happening at $CYDY.
This story is perfect for the TV show on CNBC "American Greed"
https://zlk-core-prod.s3.amazonaws.com/core/storage/app/cases/13564/events/12319/US_DIS_WAWD_3_21cv5190_83_AMENDED_COMPLAINT_for_Violations_of_the_Federal_Se_1640278818.pdf
Thank you, much appreciated. I'm more the SEC filings versus courtroom filing research.
$CYDY is a classic hype driven stock selling scheme.
LOL, yep it's gotta all be some sort of BP conspiracy.... LOL!!!
I'm not sure, can you provide a link or summary. I think all I saw was out of Vancouver.
$CYDY most definitely fits the pattern of a stock promotion, but has it conducted illegal activities in timing and communications?
That's to be determined.
Now that getting up there in volume size.
I think they mean a "form 4", so the question becomes, is a form 4 required for all rule 144 transactions?
Form 4 is required of all "insiders" sales, but not of all rule 144 sales are done by "insiders" so there is no form 4 for this transaction.
OK... Free Leronlimab!!!! And remember the joy of capital gain offsets like $CYDY!
That's nice service! I truly appreciate a good "back office". The "costs of compliance" have been reduced so much with automation, it's worthwhile for firms large and small.
"1.) Form 144: Early in that distant one week run up to $10.01, I asked my very large Valley Forge broker if they would hold my shares. They said no. I called again during that week after a close at $4.99. They said no. The next day, with a close above $5, they called me and said they would hold my shares.
Now, they call me every 90 days, to help me fill out my Form 144, keeping it current and keeping me ready to sell.
Yea it sucks and why I quickly went hard bearish after I read the last full 10-K.
It's OK to lose on biotech plays, but the key is to minimize said losses. Or better yet, AVOID a loss in the first place and don't select garbage like $CYDY.
Plus, biotech adds spice to an otherwise often drone job.
$CYDY won't last 1 more year, let alone long enough for a "10 year plan"
Leronlimab may have a 10 year life, but not the entity known as $CYDY.
"Mark this post" as they say.
I bet there will be reforms in disclosure language soon.
I think the SEC wants to prove it's worth and the DOJ is more than happy to accommodate them in their goal.
Free Leronlimab!!!!
"American Greed" new episodes are starting soon. Wonder if the producers will take on the Nader Narratives... LOL!
This is the part of rule 144 that requires special handling.
Volume limitation. The amount of securities that can be sold in any three-month period for listed companies is limited to the greater of
(i)one percent of the shares or other units of that class outstanding, or (ii) the average weekly trading volume during the four calendar weeks preceding the filing of a Form 144, or if no such notice is required, the
date of receipt of the order to execute the transaction. The amount of securities that can be sold in any three-month period for companies with over-the-counter, or OTC, securities is limited to one percent of the shares or other units of that class outstanding.
Interesting find, I'm sure I must have seen that in a filing, but $CYDY has a ridiculous "notes" section. Primarily notices of equity strike price reductions for convertible notes and warrant holders.
The final exit could get ugly on this one.
Slice and dice, and slow churn is what MM's want, but I think some size may hit the bid side today.
Oh I bet there is a lot more of similar activities to be found.
I bet they got ~$4 per share or more selling the pump.
New 52 weeks lows hourly....
Many hard lessons are to be learned by $CYDY shareholders.
Sorry Beantown Sports Nuts..$CYDY was a poor choice...
Unfortunately for "LONGS" the realization $CYDY equity is WORTHLESS is becoming apparent.
Regardless what the fees are, it's money NOT spent on scientific operations.
$CYDY management is so pitiful it funny.
Fife isn't done. He has plenty of 6 month held shares as low as $0.30 that will be continually sold into the market.
The days of Fife selling the pumps is OVER. This is the part where toxic lenders get nasty to recoup every penny possible before the share price drops below their warrants and other convertible instrument strike prices.
If we value Leronlimab at $200 million, which is fair given the lack of statistical trial proof of efficacy beside a long shot in HIV and maybe TNBC, the common equity is worthless once all the toxic debt is paid off.
The bottom line is $CYDY equity is worthless, in fact shareholder equity as a financial calculation is negative. The updated value will be out in the financials in about 2 weeks.
The 10-Q is gonna be soooo ugly!
Leronlimab as a compound might be worth $200 million, but when entangled within $CYDY's toxic weight it's worthless.
New 52 week low today with more selling set for tomorrow.